Key Factors in Later-Line CRC Tx
Key Factors Influencing Later-Line Treatment Selection for Patients With Metastatic Colorectal Cancer

Released: December 17, 2021

Expiration: December 16, 2022

Chiara Cremolini
Chiara Cremolini, MD, PhD
Teresa Macarulla
Teresa Macarulla, MD

Activity

Progress
1
Course Completed

In this episode, Chiara Cremolini, MD, PhD, and Teresa Macarulla, MD, PhD, discuss the clinical data that inform how they select regorafenib and TAS-102 as later-line treatment for patients with mCRC, with topics including:

  • Transitioning from second- to third-line therapy
  • Factors in selecting among available therapies
  • Key predictors of improved outcomes with regorafenib vs TAS-102